13 results on '"Judith M, Silverman"'
Search Results
2. O5‐06‐01: SELECTIVE TARGETING OF AMYLOID‐BETA OLIGOMER SPECIES BY PMN310, A MONOCLONAL ANTIBODY RATIONALLY DESIGNED FOR GREATER THERAPEUTIC POTENCY IN ALZHEIMER'S DISEASE
3. P2‐048: HUMANIZED PMN310 SHOWS ENHANCED THERAPEUTIC POTENTIAL BY BINDING TOXIC LOW MOLECULAR WEIGHT Aβ OLIGOMERS WHILE AVOIDING ARIA‐RELATED BINDING TO Aβ DEPOSITS IN AD PATIENT BRAINS
4. [P3–182]: PROPAGATIVE TOXIC Aβ OLIGOMER SUBCLASS IDENTIFIED AND DEFINED BY SOLVENT ORIENTATION OF THE LYSINE 28 SIDE CHAIN
5. P3‐047: The Amyloid‐Beta (Aβ) Oligomer‐Specific CYCLIC‐SER‐ASN‐LYS (CSNK) Tripeptide is Highly Immunogenic and Induces Sustained Levels of ANTI‐CSNK Antibodies of the IGG1 Subclass
6. P4‐400: Novel Amyloid‐β Oligomer‐Specific Epitopes: a Hypothesis Driven Approach to Alzheimer's Immunotherapeutics
7. P4‐299: A Computational Method to Predict Disease‐Specific Epitopes in Aβ, and its Application to Oligomer‐Selective Antibodies for Alzheimer’S Immunotherapy
8. P4‐314: Epitope‐specific amyloid‐β oligomer vaccination ameliorates amygdala‐dependent memory deficits and inhibits region‐to‐region spread of plaque pathology in APP/PS1 mice
9. O4‐04‐01: Characterization of a humanized amyloid beta oligomer monoclonal antibody (5E3) under preclinical development for passive immunotherapy of Alzheimer's disease
10. O1‐05‐04: An amyloid‐beta oligomer epitope specific for toxic assemblages in Alzheimer's disease
11. P4‐371: PRECLINICAL DEVELOPMENT OF AN AMYLOID‐B OLIGMER (ABO) SPECIFIC MONOCLONAL ANTIBODY (5E3) FOR POTENTIAL PASSIVE IMMUNOTHERAPY OF ALZHEIMER'S DISEASE
12. P4–289: Normal healthy donors possess plasma IgG reactive to a neutralizing epitope for toxic and amyloid‐seeding beta‐amyloid oligomers
13. O4‐06‐03: An immunological epitope specific for toxic oligomeric Aß in Alzheimer's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.